Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6216372 | Seminars in Diagnostic Pathology | 2015 | 9 Pages |
Abstract
Most clinically actionable alterations in lung adenocarcinomas are detected using molecular or cytogenetic techniques. However, many such alterations have a protein-level correlate that can be interrogated using immunohistochemistry. This review will summarize the therapeutic relevance of predictive biomarkers in lung adenocarcinoma including the oncogenes EGFR, MET, ALK, RET, and ROS1 and tumor suppressors PTEN and LKB1 with an emphasis on established and emerging protein immunohistochemistry reagents and their promise in clinical practice.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
Lynette M. MD,